ArticleBreast cancer : basic and clinical research2022

First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG.

Alan Celik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.